All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
Join our
Treating classical Hodgkin lymphoma: Spotlight on targeted therapies
with Gilles Salles, Paul Bröckelmann, and Ann S. LaCasce
Saturday, November 2, 2024
8:50-9:50 CET
This independent educational activity is sponsored by Takeda. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
The efficacy of ruxolitinib (RUX) is dependent on continuous administration in patients with myeloproliferative neoplasms.1 Discontinuation is associated with splenomegaly re-expansion and disease symptoms in myelofibrosis (MF) and increased hematocrit levels and disease symptoms in polycythemia vera (PV).1 Overall, poor adherence increases the risk of treatment failure.
Recently, Palandri et al.1 published results from the RAMP study (NCT06078319) in the Annals of Hematology, evaluating the incidence of low adherence to RUX and associated factors, including psychological stress, in patients with MF and PV.
Figure 1. Percentage of patients with MF or PV who completed all tests and declared A low adherence to RUX and B a high level of distress*
A
B
MF, myelofibrosis; PV, polycythemia vera.
*Adapted from Palandri, et al.1
Key learnings |
---|
|
Your opinion matters
Subscribe to get the best content related to MPN delivered to your inbox